In vivo, fingolimod is phosphorylated to form fingolimod-phosphate, which resembles naturally occurring sphingosine 1-phosphate (S1P). S1P exerts diverse physiological actions by activating its cognate G protein-coupled receptors. These receptors are expressed on a wide range of cells that are involved in many biological processes relevant to MS. These receptors have 5 types. Type 1 (S1P1) plays a key role in the immune system, regulating lymphocyte egress from lymphoid tissues into the circulation. Fingolimod-phosphate initially activates lymphocyte S1P1 via high-affinity receptor binding yet subsequently induces S1P1 down-regulation that prevents lymphocyte egress from lymphoid tissues, thereby reducing auto aggressive lymphocyte infiltration into the central nervous system (CNS). S1P receptors are also expressed by many CNS cell types and have been shown to influence cell proliferation, morphology, and migration. Fingolimod crosses the blood-brain barrier and may therefore have direct CNS effects, distinguishing it from immunologically targeted MS therapies.
1th polyethylene plastic bag. 2th. Three layered aluminum foil.
Store in a refrigerator in a well-closed container